TGen-TD2-Scottsdale Healthcare breast cancer pilot study shows value of proteomic mapping

The Side-Out Foundation’s breast cancer pilot study, led by the Translational Genomics Research Institute, Translational Drug Development and Scottsdale Healthcare, has shown that cancer patients do better when their treatment is guided by molecular profiling. Specifically, 52 percent of patients with advanced breast cancer received clinical benefit — meaning their disease was controlled for a longer time — when their cancer was treated based on addressing the abnormal proteins in their tumor…

Fuente : http://www.eurekalert.org/pub_releases/2013-07/ttg…



Hacer un comentario